Plain-English translation of NCT07631793 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called YKYY031, which is given as an injection to treat advanced solid tumors (like colorectal or pancreatic cancer) that have not responded to standard treatments. The study will measure how safe the medication is, how your body processes it, and whether it can help shrink your tumor. Researchers will gradually test higher doses and enroll more patients to learn the best dose and identify side effects.
Many patients with advanced cancers run out of effective treatment options after standard therapies fail. This medication is designed to target specific genetic mutations found in some cancers, offering a new approach for patients who have no other viable treatments available.
You likely qualify if…
You likely don't qualify if…
You will receive a single intramuscular injection of the study medication at a carefully determined dose. The trial uses a dose-escalation design, meaning early patients receive lower doses, and doses are gradually increased as safety is confirmed, with additional patients enrolled at the highest safe dose. You will have regular follow-up visits and tests to monitor how your body tolerates the medication, how it moves through your body, and whether your tumor responds to treatment.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
China